Aarti Drugs Limited

BSE
AARTIDRUGS
Stock
Yield per half year: +3.12%
Dividend yield: 0.2464%

470.75 ₹

+2.95 ₹ +0.6306%
321.5 ₹
606.35 ₹

Min/max per year

Share chart Aarti Drugs Limited

About Aarti Drugs Limited

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally.

more details
The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Main settings

ISIN
INE767A01016
Industry
Pharmaceuticals
Sector
Health Care
Валюта
inr
Валюта отчета
inr
Див.доход ао
0.2464
Дивиденд ао
1
Сайт

Grade

Underestimation
Title Value Grade
P/S 1.66 8
P/BV 3.27 5
P/E 24.43 6
Efficiency
Title Value Grade
ROA 7.06 2
ROE 13.86 4
ROIC 9.79 3
Dividends
Title Value Grade
Dividend yield 0.2464 0.63
DSI 0.9286 9.29
Average dividend growth -16.2 0
Debt
Title Value Grade
Debt/EBITDA 1.83 7
Debt/Ratio 0.2312 10
Debt/Equity 0.8974 9
Growth impulse
Title Value Grade
Yield Revenue, % 10.78 2
Yield Ebitda, % 44.13 6
Yield EPS, % -66.08 0

Prices

Price Min. Max. Change Changes in the industry Changes in the index
Yesterday 467.8 ₹ 0 ₹ 0 ₹ 0.63 % 0 % 0 %
Week 469.4 ₹ 0 ₹ 0 ₹ 0.29 % 0 % 0 %
Month 350.7 ₹ 428.1 ₹ 481.45 ₹ 34.23 % 0 % 0 %
Three month 373.3 ₹ 321.5 ₹ 481.45 ₹ 26.11 % 0 % 0 %
Half a year 456.5 ₹ 321.5 ₹ 481.45 ₹ 3.12 % 0 % 0 %
Year 482.25 ₹ 321.5 ₹ 606.35 ₹ -2.38 % 0 % 0 %
3 years 412.55 ₹ 316.95 ₹ 618.35 ₹ 14.11 % 0 % 0 %
5 years 658.45 ₹ 316.95 ₹ 3 435 ₹ -28.51 % 0 % 0 %
10 years 0 ₹ 316.95 ₹ 3 435 ₹ 0 % 0 % 0 %
Year to date 433.2 ₹ 321.5 ₹ 481.45 ₹ 8.67 % 0 % 0 %

Company management

Head Job title Payment Year of birth
Mr. Prakash Moreshwar Patil Chairman, MD, CEO & Head of BR 27.65M 1947 (78 years)
Mr. Harshit Manila Savla Joint MD & Executive Director 25.55M 1962 (63 years)
Mr. Harit Pragji Shah Whole-Time Director 25.55M 1963 (62 years)
Mr. Uday Moreshwar Patil Whole-Time Director 3.19M 1963 (62 years)
Mr. Rashesh Chandrakant Gogri MD & Executive Director 25.55M 1974 (51 year)
Mr. Adhish Prakash Patil CFO & COO N/A 1983 (42 years)
Mr. Dhanaji L. Kakade Vice President of Technical N/A
Mr. Vishwa Harshit Savla Managing Director of the Pinnacle Life Science Private Limited N/A
Mr. Rushikesh Vivek Deole Company Secretary & Compliance Officer N/A

About company

Address: India, Mumbai, Mahendra Industrial Estate - Open in google maps, Open in yandex maps
Website: https://www.aartidrugs.co.in